Impact of Fostamatinib on Inflammatory Biomarkers in Hospitalized Patients With COVID-19.
Raquel S Da Cruz, Heather L Teague, Marcos J Ramos-Benitez, Sonya J Malavez-Cajigas, Trenton Williams, Rui Miao, Xin Tian, Gefei Lin, Laurence W Busse, Akram Khan, Ari Moskowitz, David N Hager, Todd W Rice, Adit A Ginde, Nicole M Iovine, Peter Chen, Basmah Safdar, Kevin W Gibbs, Ali Javaheri, Marjolein de Wit, Michelle Harkins, Kris Hudock, Lisa H Merck, Aaron Barksdale, Jeffrey M Sturek, Harry Schrager, Nathan I Shapiro, Michael Lanspa, Estelle Harris, Subhashini Sellers, Andrew J Goodwin, Mark A Tidswell, Michael R Filbin, Matthew S Shotwell, Matthew W Semler, Wesley H Self, Sean P Collins, Jeffrey R Strich, Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-4) Host Tissue Investigators
Crit Care Explor 8(7) e1405
摘要
摘要
OBJECTIVES: Understanding the mechanistic impact of fostamatinib, a spleen tyrosine kinase inhibitor, in severe COVID-19 using biomarkers associated with disease severity is crucial for the development of host-directed therapeutics. We analyzed samples from a randomized clinical trial to investigate the impact of fostamatinib on multiple inflammatory biomarkers associated with COVID-19 disease severity. DESIGN: Secondary analyses of biomarkers from a randomized clinical trial. SETTING: Multicenter randomized clinical trial. PATIENTS: A total of 400 adults hospitalized with COVID-19 were enrolled in a phase 3 randomized clinical trial. Absolute neutrophil counts (ANCs) were analyzed across 392 patients and biomarkers were measured in 190 patients with available plasma samples. INTERVENTIONS: Adults hospitalized with COVID-19 were randomized to receive either fostamatinib (150 mg bid) or placebo. ANCs and 24 biomarkers were assessed at day 0 and over time using a multiplexed Meso Scale Discovery assay (Meso Scale Diagnostics LLC, Rockville, MD). MEASUREMENTS AND MAIN RESULTS: At day 0, participants with World Health Organization ordinal scale 5-7 had elevated ANC counts, compared with ordinal scale 4. In addition, the levels of neutrophil-associated biomarkers, inflammatory cytokines, and mediators of endothelial dysfunction at day 0 were increased in the participants who were ordinal scale 5-7 vs. ordinal scale 4. Randomization to fostamatinib compared with placebo resulted in a decrease in ANC and several neutrophil-associated biomarkers, pro-inflammatory cytokines, and mediators of endothelial dysfunction/tissue damage. This differential finding was also demonstrated in a subgroup of patients (n = 85) with a hypoinflammatory phenotype. LIMITATIONS: Missing plasma samples and neutral phase 3 trial results. CONCLUSIONS: Randomization to fostamatinib resulted in lower neutrophil counts and levels of circulating biomarkers in hospitalized patients with COVID-19; however, the observed impact of fostamatinib was modest compared with prior studies.
KM 提取结果
0 个 Figure · 0 个 KM 面板
其他 Figure(2,默认折叠)
这些图片未产生 KM 曲线结果,不在主页面重复展示。